case_images: PMC4400458_01
case_images: Renal arteriolar wall thickening, mild interstitial fibrosis and tubular atrophy areas.
case_images: ndtplussfr157f01_ht.jpg
case_images: PMC4400458_01_ndtplussfr157f01_ht.jpg
case_images: fig1
case_images: Renal biopsy (Figure 1) conducted the second week after admission revealed occlusive thrombosis in several small- and medium-sized arteries with secondary ischaemic glomerular changes.
case_images: Ischaemic glomeruli and artery wall thickening with thrombotic microangiopathy changes.
case_images: ndtplussfr157f02_ht.jpg
case_images: PMC4400458_01_ndtplussfr157f02_ht.jpg
case_images: fig2
case_images: A second renal biopsy (Figure 2) performed 2.5 months after admission, and 3 weeks before starting eculizumab, showed changes similar to those observed at the first biopsy: thrombotic microangiopathic lesions persisted and there was deterioration of interstitial fibrosis and tubular atrophy.